NU7441 (KU-57788)
目录号:S2638 Purity: 99.94%
NU7441 (KU-57788)是一种高度有效的,选择性DNA-PK抑制剂,在无细胞试验中IC50为14 nM,也会抑制 mTOR 和 PI3K,对应的IC50值分别为1.7 μM和5 μM。它可降低NHEJ的频率,而增强Cas9介导DNA剪接后发生的同源重组修复率。
CAS: 503468-95-9
客户使用Selleck的NU7441 (KU-57788)发表文献281篇
- Nat Cell Biol, 2024 10.1038/s41556-024-01394-y
- Nature, 2023 623(7985):183-192
- Cell Discov, 2023 9(1):26
- Cell Metab, 2022 S1550-4131(21)00542-8
- Cell Res, 2021 10.1038/s41422-021-00528-3
- Immunity, 2021 S1074-7613(21)00069-8
- Protein Cell, 2021 10.1007/s13238-021-00879-y 10.1126/science.abc5386
- Nature, 2020 10.1038/s41586-020-2960-y
- Signal Transduct Target Ther, 2020 4;5(1):20
- Sci Immunol, 2020 5(43)
- Blood, 2020 5 pii: blood
- Nature, 2019 74(7779):571-574
- Cell, 2019 36(2):179-193
- Cancer Cell, 2019 36(2):179-193
- Cancer Cell, 2018 34(3):396-410
- Cell Res, 2018 28(7):756-770
- Nat Biotechnol, 2017 35(5):463-474
- Nat Cell Biol, 2016 18(11):1196-1207
- Blood, 2016 128(4):574-83
- Nat Cell Biol, 2015 17(9):1158-68
- Nat Commun, 2024 15(1):6517
- Nat Commun, 2024 15(1):7076
- Nat Commun, 2024 15(1):2089
- J Clin Invest, 2024 e180278
- Nucleic Acids Res, 2024 gkad1224
- Nucleic Acids Res, 2024 gkae1207
- Nucleic Acids Res, 2024 gkae807
- Theranostics, 2024 14(4):1561-1582
- J Exp Clin Cancer Res, 2024 43(1):163
- Research (Wash D C), 2024 7:0331
- Clin Transl Med, 2024 14(5):e1690
- Genes Dev, 2024 38(1-2):70-94
- MedComm (2020), 2024 5(8):e690
- PLoS Biol, 2024 22(3):e3002552
- Cell Rep, 2024 43(5):114205
- Cell Death Discov, 2024 10(1):434
- iScience, 2024 27(9):110826
- iScience, 2024 27(7):110306
- Cancers (Basel), 2024 16(19)3291
- Sci Rep, 2024 14(1):19999
- Genes (Basel), 2024 15(6)808
- PeerJ, 2024 12:e18489
- bioRxiv, 2024 2024.08.19.608673
- bioRxiv, 2024 2024.09.25.615014
- Data Brief, 2024 53:110183
- Nat Struct Mol Biol, 2023 30(1):99-106
- Nat Struct Mol Biol, 2023 10.1038/s41594-023-00929-5
- Nat Commun, 2023 14(1):4003
- Nat Commun, 2023 14(1):3172
- Nat Commun, 2023 14(1):8293
- Mol Cell, 2023 83(14):2434-2448.e7
- Nucleic Acids Res, 2023 10.1093/nar/gkad973
- Nucleic Acids Res, 2023 gkad791
- Nucleic Acids Res, 2023 gkad533
- Nucleic Acids Res, 2023 51(13):6770-6783
- Cell Death Differ, 2023 10.1038/s41418-023-01167-4
- J Exp Clin Cancer Res, 2023 42(1):256
- Cell Rep, 2023 42(8):112805
- Cell Rep, 2023 42(2):112019
- Oncogene, 2023 42(26):2113-2125
- Elife, 2023 12e81923
- EMBO Rep, 2023 e57234.
- Mol Cell Proteomics, 2023 22(3):100503
- Int J Mol Sci, 2023 24(3)2498
- Am J Cancer Res, 2023 13(2):452-463
- J Biol Chem, 2023 299(3):102991
- Front Oncol, 2023 13:1287444
- Viruses, 2023 15(6)1243
- bioRxiv, 2023 2023.08.08.552428
- bioRxiv, 2023 2023.04.21.537819
- Biomed Rep, 2023 18(4):28
- bioRxiv, 2023 2023.09.05.556391
- Nat Commun, 2022 13(1):5295
- Nat Commun, 2022 13(1):3016
- Mol Cell, 2022 82-20:3932-3942.e6
- Mol Cell, 2022 S1097-2765(22)00393-8
- Nucleic Acids Res, 2022 gkac375
- Nucleic Acids Res, 2022 50(18):10503-10525
- Nucleic Acids Res, 2022 50(14):8060-8079
- Clin Cancer Res, 2022 clincanres.1846.2021
- Cancer Res, 2022 82(24):4571-4585.
- EMBO Mol Med, 2022 e14501
- Cell Rep, 2022 42(1):111909
- Cell Rep, 2022 38(7):110396
- Oncogene, 2022 10.1038/s41388-022-02384-w
- Phytomedicine, 2022 99:153977
- Elife, 2022 11e74700
- Stem Cell Res Ther, 2022 13(1):440
- Sci Signal, 2022 15(725):eabh1121
- PLoS Pathog, 2022 18(2):e1010275
- Cells, 2022 11(13)2099
- NPJ Breast Cancer, 2022 8(1):31
- Open Biol, 2022 12(10):220213
- iScience, 2022 25(9):104892
- Int J Mol Sci, 2022 23(2)633
- Pharmaceutics, 2022 14(8)1525
- Am J Cancer Res, 2022 12(5):2363-2375
- Virulence, 2022 13(1):241-257
- Cancers (Basel), 2022 14(13)3186
- FASEB J, 2022 36(3):e22221
- Front Oncol, 2022 12:941638
- Front Oncol, 2022 12:1043538
- ACS Omega, 2022 7(3):2571-2582
- Cell Biol Int, 2022 10.1002/cbin.11900
- Radiat Res, 2022 198(4):336-346
- Genesis, 2022 60(1-2):e23465
- NAR Cancer, 2022 4(2):zcac012
- Sci Transl Med, 2021 13(600)eabc7275
- Sci Transl Med, 2021 13(580)eabc4465
- Sci Transl Med, 2021 13(587)eabg1168
- Nat Commun, 2021 12(1):6560
- Nat Commun, 2021 12(1):5748
- Nat Commun, 2021 12(1):6561
- J Clin Invest, 2021 131(11)146256
- Nucleic Acids Res, 2021 gkab262
- Nucleic Acids Res, 2021 gkab051
- Nucleic Acids Res, 2021 gkab743
- Nucleic Acids Res, 2021 49(9):5095-5105
- J Exp Clin Cancer Res, 2021 40(1):224
- Int J Biol Sci, 2021 17(4):1026-1040
- Int J Biol Sci, 2021 17(4): 1026-1040
- Cell Rep, 2021 37(2):109815
- Acta Pharmacol Sin, 2021 10.1038/s41401-020-00577-1
- JCI Insight, 2021 e154402
- Sci Signal, 2021 14(705):eabc4764
- Cell Mol Gastroenterol Hepatol, 2021 S2352-345X(21)00249-6
- Commun Biol, 2021 4(1):484
- Int J Mol Sci, 2021 22(19)10512
- Front Cell Dev Biol, 2021 9:810928
- FEBS J, 2021 10.1111/febs.16321
- Cancers (Basel), 2021 13(4)830
- Mol Cancer Res, 2021 molcanres.0301.2021
- Cancers (Basel), 2021 13(15)3717
- J Biol Chem, 2021 297(4):101209
- Cell Signal, 2021 S0898-6568(21)00195-9
- Med Phys, 2021 48(6):3243-3261
- Chembiochem, 2021 22(12):2177-2181
- Biochem Biophys Res Commun, 2021 553:51-57
- Mol Biol Rep, 2021 10.1007/s11033-020-06124-9
- FEBS Open Bio, 2021 10.1002/2211-5463.13198
- Sci Adv, 2021 7(25)eabg6680
- SSRN, 2021 10.2139/ssrn.3972034
- Mol Biomed, 2021 2(1):19
- Nat Commun, 2020 11(1):5775
- Nat Commun, 2020 11(1):6182
- Mol Cell, 2020 S1097-2765(20)30723-1
- Adv Sci (Weinh), 2020 7(20):2000157
- Nucleic Acids Res, 2020 48(2):736-747
- Nucleic Acids Res, 2020 10.1093/nar/gkaa022
- Nucleic Acids Res, 2020 gkaa782
- Clin Cancer Res, 2020 10.1158/1078-0432.CCR-20-2269
- Cell Rep, 2020 32(8):108068
- Cell Rep, 2020 32(11):108140
- Cell Rep, 2020 33(2):108240
- Cell Rep, 2020 32(6):108018
- J Cell Biol, 2020 219(11)e202001063
- Elife, 2020 9:e57894
- Biomed Pharmacother, 2020 129:110427
- Mol Oncol, 2020 26
- J Cell Physiol, 2020 10.1002/jcp.29927
- Int J Mol Sci, 2020 21(17)E6383
- Int J Mol Med, 2020 45(6):1673-1684
- Oncotarget, 2020 11(7):699-726
- Cancers (Basel), 2020 12(9):E2356
- Cancers (Basel), 2020 12(6):1490
- Mol Cancer Res, 2020 10.1158/1541-7786.MCR-19-0507
- Int J Oncol, 2020 57(4):939-955
- J Biol Chem, 2020 295(1):125-137
- Front Oncol, 2020 10:575711
- Toxicol Lett, 2020 318:104-113
- Int J Radiat Biol, 2020 1-7
- University of Lübeck, 2020 N/A
- NAR Cancer, 2020 2(2):zcaa006
- Nat Commun, 2019 10(1):5304
- Nat Commun, 2019 10(1):1577
- Nat Commun, 2019 10(1):3925
- Nat Commun, 2019 10(1):2866
- Nucleic Acids Res, 2019 47(21):10977-10993
- Nucleic Acids Res, 2019 47(18):9467-9479
- Nucleic Acids Res, 2019 47(16):8838-8859
- Clin Cancer Res, 2019 25(18):5608-5622
- Genes Dev, 2019 33(17-18):1175-1190
- Haematologica, 2019 104(11):2225-2240
- Cell Rep, 2019 29(11):3708-3725.e5
- Br J Cancer, 2019 121(7):600-610
- J Environ Manage, 2019 244:77-82
- Oncogene, 2019 38(14):2451-2463
- J Cell Biol, 2019 218(7):2113-2123
- Int J Cancer, 2019 10.1002/ijc.32558
- Int J Mol Sci, 2019 20(24)E6316
- Mol Cell Biol, 2019 39(24)e00181-19
- Cancers (Basel), 2019 11(9)
- Mol Cancer Res, 2019 17(12):2457-2468
- FASEB J, 2019 33(1):1138-1150
- FASEB J, 2019 33(11):11668-11681
- FASEB J, 2019 33(6):6778-6788
- J Biol Chem, 2019 294(8):2827-2838
- PLoS Genet, 2019 15(2):e1007925
- Front Physiol, 2019 10:616
- Toxicol Sci, 2019 10.1093/toxsci/kfz178
- J Pharmacol Exp Ther, 2019 371(2):320-326
- Mol Med Rep, 2019 20(4):3609-3616
- Retrovirology, 2019 16(1):13
- BMC Pulm Med, 2019 19(1-:165
- Mol Biol Rep, 2019 10.1007/s11033-019-04605-0
- Mol Biol Rep, 2019 10.1007/s11033-019-05105-x
- FEBS Open Bio, 2019 9(7):1315-1326
- Nat Commun, 2018 9(1):5351
- Nucleic Acids Res, 2018 46(10):5050-5060
- Nucleic Acids Res, 2018 46(17):8926-8939
- Clin Cancer Res, 2018 24(23):6001-6014
- Cell Death Dis, 2018 9(9):931
- Cell Rep, 2018 24(4):987-1000
- JCI Insight, 2018 3(3)98096
- Int J Cancer, 2018
- Mol Cancer Ther, 2018 17(12):2551-2563
- Int J Mol Sci, 2018
- Oncotarget, 2018 9(9):8560-8572
- Mol Cancer Res, 2018 16(8):1241-1254
- Mol Cancer Res, 2018 16(3):428-438
- FASEB J, 2018 32(4):1818-1829
- Sci Rep, 2018 8(1):9685
- Sci Rep, 2018 8(1):14421
- DNA Repair (Amst), 2018 68:12-24
- DNA Repair (Amst), 2018 68:68-74
- Hum Mol Genet, 2018 27(23):4024-4035
- Mol Biol Cell, 2018 29(15):1786-1797
- Biochem Biophys Rep, 2018 16:115-121
- Nucleic Acids Res, 2017 45(1):244-254
- Cancer Res, 2017 77(17):4567-4578
- Cancer Res, 2017 77(18):4745-4754
- Cancer Immunol Res, 2017 5(9):790-803
- J Cell Biol, 2017 216(3):623-639
- EMBO Rep, 2017 18(8):1412-1428
- Cell Death Discov, 2017 3:17072
- Oncotarget, 2017 8(52):90037-90049
- Oncotarget, 2017 8(2):2916-2935
- J Biol Chem, 2017 292(30):12424-12435
- Int J Biochem Cell Biol, 2017 92:164-172
- DNA Repair (Amst), 2017 54:30-39
- PLoS One, 2017 12(7):e0181608
- Radiat Res, 2017 188(6):597-604
- Mol Biol Cell, 2017 28(26):3756-3772
- Nat Commun, 2016 7:12880
- Nucleic Acids Res, 2016 44(11):5204-17
- Nucleic Acids Res, 2016 44(8):3695-712
- Cancer Lett, 2016 383(1):41-52
- Cell Death Dis, 2016 7(7):e2316
- Oncogene, 2016 35(5):577-586
- Oncotarget, 2016 7(38):60807-60822
- Oncotarget, 2016 7(40):65504-65513
- Sci Rep, 2016 6:22972
- Cell Cycle, 2016 15(1):84-94
- PLoS One, 2016 11(12):e0167454
- PLoS One, 2016 11(5):e0155230
- PLoS One, 2016 11(9):e0163049
- Mutat Res Genet Toxicol Environ Mutagen, 2016 795:1-6
- Genome Med, 2015 10.1186/s13073-015-0215-6
- Leukemia, 2015 29(5):1133-42
- Mol Cancer Ther, 2015 14(8):1896-906
- Oncotarget, 2015 6(16):14005-25
- Mol Cancer Res, 2015 13(1):120-9
- J Biol Chem, 2015 290(46):27545-56
- Cell Cycle, 2015 14(23):3713-24
- PLoS ONE, 2015
- Cancer Biol Ther, 2015 16(11):1585-92
- Anticancer Res, 2015 35(7):3829-38
- Nucleic Acids Res, 2014 42(12):7776-92
- Nucleic Acids Res, 2014 42(9):5616-32
- Cancer Res, 2014 74(16):4282-94
- Genes Dev, 2014 28(8):875-87
- Oncogene, 2014 10.1038/onc.2014.268
- ACS Chem Biol, 2014 9(5):1160-71
- Biosci Rep, 2014 34(3)
- Toxicol Sci, 2014 10.1093/toxsci/kfu207
- Uppsala University, 2014 Department of Radiology
- Mutat Res, 2014 769:1-10
- Nucleic Acids Res, 2013 41(22):10157-69
- Nucleic Acids Res, 2013 41(7):4080-92
- Nucleic Acids Res, 2013 41(15):7378-86
- Int J Radiat Oncol Biol Phys, 2013 88(2):385-94
化学信息&溶解度
分子量 | 413.49 |
分子式 | C25H19NO3S |
CAS号 | 503468-95-9 |
Smiles | C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC5=C4SC6=CC=CC=C56 |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 5 mg/mL ( 12.09 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 3 mg/mL ( 7.25 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : Insoluble ( DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 15 mg/mL ( 36.27 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 3 mg/mL ( 7.25 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
5%DMSO
40%PEG300
5%Tween80
50%ddH2O
浓度:0.75mg/ml
(1.81mM)
操作示例:以 1 mL 工作液为例,取50μL15mg/ml的澄清DMSO储备液加到400μLPEG300中,混合均匀使其澄清;向上述体系中加入50μLTween80,混合均匀使其澄清;然后继续加入500μLddH2O定容至1mL。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。